Research notes

Guidance rest and expectations move lower - FY27 guidance implies a ~15% production downgrade versus consensus even at the top end of the range, while C1 costs and AISC are ~15-18% above market expectations. While FY26 was broadly in line, FY27 guidance is likely to drive a reset in earnings expectations. Honeymoon new feasibility study - The updated feasibility study outlines a more achievable development pathway with improved unit economics and lower sustaining capital intensity; however, the 13.8Mlb production profile sits below the ~15.1Mlb assumed by consensus, shifting the debate towards whether improved margins can offset lower volumes. Following material downgrades to our forecasts, we move to a SELL (previously ACCUMULATE) with a reduced-price target of A$1.30ps (previously A$1.40ps).

CCR delivered a standout FY26 result, with organic revenue growth of +9% (+12% core collections growth), complemented by strong contributions from CCR’s two acquisitions. Revenue of $60m (+28% YoY) exceeded guidance. Underlying EBITDA (excl SBP) of $10.4m (+41% YoY) was also strong. FY27 guidance of $73-77m revenue (+21-28% growth) and EBITDA of $12-14m (+14-33% YoY) was largely consistent with our expectations, with CCR pointing to a solid pipeline and further international growth opportunities underpinning this outlook. We upgrade our revenue/EBITDA forecasts by 3% in FY27/28F, with our price target unchanged at $0.30/share.

MX1 posted its FY26 result which was slightly ahead of our forecasts. We have made some modest downward revisions to our forecasts which see our TP now at A$0.06 (was $0.08). We have moved to a HOLD recommendation (was SPECULATIVE BUY) preferring to wait for evidence of some sales momentum with the Rover following a restructure of that division.

The FY26 result beat expectations with EBITDA of $318m +77% yoy and +7% vs MorgansF/consensus and NPAT of $178m +295% and +11%. The audited result does not change our view given FY27 guidance was already flagged in August, and we remain positive on AIS' leverage to strong copper and gold prices across Tritton and Cracow. We maintain a BUY rating with a A$0.63ps target price (previously A$0.55).

The FY26 result was robust, and the order book stands at $1.4bn which almost entirely de-risks FY27. Further tendering activity across a heavy pipeline of projects across resources and public infrastructure should ensure an even stronger FY28, positioning CVL for an upgrade cycle. Moreover, prospects of winning defence work continue to strengthen, for both naval shipbuilding and the construction of the defence precinct at Henderson. This comes as a free option. We lift FY27-28 EBITDA +7-8% and our target price to $2.40 (from $2.30). BUY.

VEE’s FY26 result was in line with expectations and management’s guidance provided in June. FY26 was a transitional year for VEE, with revenue declining 25% and underlying EBITDA falling 61%, reflecting a downturn in the global marine market that weighed on propulsion revenue along with materially lower gyro orders. Encouragingly, propulsion revenue recovered in late FY26 and demand is expected to strengthen further in FY27. Gyro revenue should also improve as the full Mark III range becomes available over the next few months. With Defence opportunities continuing to progress, we remain positive on VEE’s long-term outlook, although the timing of order flow can cause earnings volatility in the near term. SPECULATIVE BUY rating maintained.

CUV's FY26 result was soft, delivering the first annual revenue decline in the company’s history. The bigger story, though, is the Board's open consideration of a full Nasdaq listing and an ASX delisting. We lower our EPP assumptions, which have taken a competitive hit. FY26 earnings were flattered by R&D timing that we expect to reverse in FY27, and the long-term case now rests almost entirely on December's Vitiligo top-line. A$252m cash is the floor. We move to a HOLD (from Speculative Buy), with a lower target price of A$10 (from A$13). Our bear case is ~$7 on a Vitiligo failure.

1H26 EBITDA of $30.5m beat MorgansF by +8% but was a 20% miss to consensus. Importantly, the balance sheet remains solid with $202m of liquidity. Golden Grove is now approaching an inflection point as 29M moves closer to Xantho Extended coming back online, along with new ore sources from Gossan Valley and Oizon in Dec-Q. We maintain a HOLD rating with a A$0.35ps target price (previously A$0.26).

The market should be broadly comfortable with the result given recent trading updates, but new contract delivery remains the key requirement before investors are likely to begin marking the stock materially higher. Revenue and OPEX landed broadly in line with guidance, while the NPAT miss was driven by a A$1.9m restructuring charge and a weaker tax benefit rather than deterioration in the core subscription business. Moderate increase in target price due to model roll-forward, lower share count, and leaner-than-expected cost base. Our target price rises to A$0.48 (from A$0.44) and we retain our Buy recommendation. Upside potential to target presents an opportunity but needs new contract momentum to spark renewed interest.

Airtasker's (ART) FY26 result was broadly in line with our expectations. Group revenue grew ~10% on pcp to A$57.8m (marketplaces revenue ex-OneFlare +15.5% to A$52m), and its earlier stage offshore marketplaces (UK/US) showed accelerating momentum and strong topline growth (+55%/150% respectively). ART also announced media deals with OML and Nova, extending the brand investment runway (media inventory to deploy from FY27 now ~A$24m). We make several changes to our assumptions across the forecast period (details below). Our price target remains unchanged at A$0.47. We retain our BUY recommendation.